METHOD FOR DETERMINING AVERAGE RATE OF FORMATION OF HEPATIC FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS C Russian patent published in 2020 - IPC A61B5/00 

FIELD: medicine.

SUBSTANCE: invention refers to medicine and can be used to determine average speed of liver fibrosis in patients with chronic hepatitis C (CHC) as an additional indication for antiviral therapy. That is ensured by assessing transient liver elastometry, APRI index and Charlson index, divided by the number of years since the last measurement. These values are compared with average values of average rate of formation of fibrosis per year, which according to elastometry are 1.1 kPa, APRI index is 0.1 points, Charlson index is 0.2 points. If observing the patient's excess by one or more of the three indicators - the rate of hepatic fibrosis is considered to be high, and the antiviral therapy is immediately recommended. If all the results of the patient with CHC are equal to average speed, the rate of hepatic fibrosis is considered to be moderate and antiviral therapy is recommended for 1–2 years. If all the values of the patient with CHC are lower than the above, the fibrosis rate is considered to be low and the length of the antiviral therapy may be postponed.

EFFECT: invention provides a choice of therapeutic approach in antiviral therapy and prevention of adverse outcomes in patients with CHC.

1 cl, 5 tbl, 3 ex